National reference levels of CT procedures dedicated for treatment planning in radiation oncology.

Objective: To present results of the first national survey on reference levels of CT imaging performed for the treatment planning purposes in radiation oncology in Croatia.

Methods: Data for CT protocols of five anatomical regions including head, head and neck, pelvis, breast, and thorax were collected at eight radiation oncology departments in Croatia. Data included volume CT dose index (CTDI), dose-length product (DLP), scan length and set of acquisition and reconstruction parameters.

Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis.

Purpose: We retrospectively evaluated the outcome in prostate cancer (PCa) patients receiving combination of adjuvant radiotherapy (ART) and androgen deprivation therapy (ADT) after radical prostatectomy (RP).

Methods: Between 2004 and 2012, 132 patients were referred for ART to the Department of Oncology, University Hospital, Split. Fifty-six consecutive patients with at least one proven or possible adverse prognostic factor such as pelvic lymph nodes invasion (LNI), lymphovascular invasion (LVI), high tumor grade and high preoperative prostatic specific antigen (PSA) level received combination of ART and ADT, while 76 patients received ART alone.

Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy.

Objectives: Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries. We present long-term outcomes of treatment with a concomitant chemobrachyradiotherapy followed by consolidation chemotherapy regimen.

Materials And Methods: We treated 118 patients with LACC (International Federation of Gynecology and Obstetrics stages IB2-IVA) with external radiotherapy (50 Gy in 25 fractions) and concomitant chemobrachyradiotherapy (low-dose rate).

Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.

Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant anthracyclines/taxanes. Based on preclinical synergy with mitomycin C (MMC) and capecitabine in human tumor xenografts, we conducted a phase II study of first-line capecitabine and MMC in MBC. Patients received 3-weekly chemotherapy comprising MMC 8 mg/m² day 1 and capecitabine 1000 mg/m² twice daily, days 1-14.

Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients.

Purpose: To evaluate the therapeutic effectiveness and safety of treatment with capecitabine and mitomycin-C (MMC) in patients with metastatic colorectal cancer previously treated with at least one chemotherapy regimen for recurrent or metastatic disease.

Patients And Methods: A total of 36 patients (male/female 21/15, median age 62.5 years) with metastatic colorectal cancer were treated with capecitabine and MMC as their second, third or fourth line chemotherapy regimen.